The renal denervation market flamed out in 2014, after four years of breakneck activity. But a resurrection of sorts is now underway, led by Medtronic and ReCor Medical. We explore the prospects for a near-term renal denervation revival and what that would mean for the medtech industry and the global hypertension community.Read Article
A founding member of the MedTech Strategist editorial team, @MaryThompsonMTS has 25+ years of experience covering technologies and trends in the medical device industry. She currently focuses on the cardiovascular, diabetes, and digital health markets. Prior to joining MedTech Strategist, Mary was Managing Editor/Executive Editor of the Medtech Insight Newsletter, a position she held for nearly 14 years, and she was instrumental in the initial conceptualization and launch of that publication. Mary’s extensive editorial experience combined with her early background as an R&D scientist brings a unique balance of expertise and perspective to her work.